Greta Wilkening
Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urea Cycle Disorders, Inborn | 3 | 2026 | 26 | 1.340 |
Why?
| | Lennox Gastaut Syndrome | 3 | 2022 | 21 | 1.010 |
Why?
| | Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2026 | 7 | 0.940 |
Why?
| | Brain Diseases | 3 | 2022 | 159 | 0.820 |
Why?
| | Neuropsychology | 3 | 2024 | 44 | 0.820 |
Why?
| | Nervous System Diseases | 2 | 2026 | 288 | 0.770 |
Why?
| | Cognition Disorders | 4 | 2026 | 559 | 0.750 |
Why?
| | Hyperammonemia | 3 | 2026 | 17 | 0.640 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2012 | 76 | 0.630 |
Why?
| | Cognitive Dysfunction | 2 | 2026 | 481 | 0.630 |
Why?
| | Memory Disorders | 2 | 2012 | 198 | 0.630 |
Why?
| | Central Nervous System Neoplasms | 2 | 2012 | 177 | 0.580 |
Why?
| | Cognition | 10 | 2024 | 1292 | 0.500 |
Why?
| | Brain Neoplasms | 4 | 2022 | 1325 | 0.490 |
Why?
| | Neurodevelopmental Disorders | 3 | 2026 | 239 | 0.430 |
Why?
| | Child Development | 4 | 2026 | 481 | 0.420 |
Why?
| | Quality of Life | 2 | 2026 | 3200 | 0.410 |
Why?
| | Adolescent | 23 | 2026 | 22557 | 0.410 |
Why?
| | Phenylketonurias | 2 | 2024 | 15 | 0.410 |
Why?
| | Neuropsychological Tests | 8 | 2024 | 1149 | 0.400 |
Why?
| | Medical Oncology | 1 | 2017 | 345 | 0.400 |
Why?
| | Mass Screening | 1 | 2022 | 1307 | 0.390 |
Why?
| | Pediatrics | 2 | 2024 | 1124 | 0.390 |
Why?
| | Child | 33 | 2026 | 22693 | 0.390 |
Why?
| | Nursing Assessment | 1 | 2012 | 53 | 0.350 |
Why?
| | Prenatal Exposure Delayed Effects | 3 | 2024 | 665 | 0.340 |
Why?
| | Child, Preschool | 21 | 2026 | 11913 | 0.320 |
Why?
| | Developmental Disabilities | 3 | 2020 | 281 | 0.300 |
Why?
| | Hemophilia A | 2 | 2024 | 150 | 0.300 |
Why?
| | Cross-Sectional Studies | 8 | 2026 | 5899 | 0.290 |
Why?
| | Autism Spectrum Disorder | 2 | 2025 | 406 | 0.290 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2025 | 2623 | 0.280 |
Why?
| | Epilepsies, Myoclonic | 2 | 2020 | 63 | 0.270 |
Why?
| | Age of Onset | 3 | 2026 | 558 | 0.270 |
Why?
| | Humans | 49 | 2026 | 146342 | 0.250 |
Why?
| | Environmental Health | 1 | 2026 | 42 | 0.230 |
Why?
| | Infertility | 1 | 2026 | 62 | 0.230 |
Why?
| | Epilepsy | 2 | 2023 | 400 | 0.230 |
Why?
| | Fertilization in Vitro | 1 | 2026 | 109 | 0.220 |
Why?
| | Young Adult | 9 | 2026 | 14330 | 0.220 |
Why?
| | Electroencephalography | 3 | 2024 | 576 | 0.220 |
Why?
| | Child Behavior | 1 | 2026 | 234 | 0.210 |
Why?
| | Brain | 5 | 2025 | 2991 | 0.200 |
Why?
| | Ammonia | 1 | 2024 | 61 | 0.200 |
Why?
| | Oxytocin | 1 | 2024 | 51 | 0.200 |
Why?
| | Male | 29 | 2026 | 73396 | 0.200 |
Why?
| | Longitudinal Studies | 4 | 2026 | 3017 | 0.200 |
Why?
| | Seizures | 3 | 2024 | 489 | 0.200 |
Why?
| | Survivors | 4 | 2017 | 526 | 0.200 |
Why?
| | Female | 32 | 2026 | 79499 | 0.200 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 2 | 2024 | 422 | 0.190 |
Why?
| | Parenting | 1 | 2026 | 309 | 0.180 |
Why?
| | Patient Selection | 1 | 2026 | 728 | 0.170 |
Why?
| | Clinical Trials as Topic | 2 | 2024 | 1064 | 0.170 |
Why?
| | Amnesia | 2 | 2012 | 47 | 0.170 |
Why?
| | Patient Reported Outcome Measures | 1 | 2026 | 516 | 0.170 |
Why?
| | Self Report | 1 | 2026 | 870 | 0.170 |
Why?
| | Infant | 10 | 2024 | 10114 | 0.170 |
Why?
| | Rare Diseases | 1 | 2022 | 117 | 0.170 |
Why?
| | Adult | 13 | 2026 | 41087 | 0.160 |
Why?
| | NAV1.2 Voltage-Gated Sodium Channel | 1 | 2020 | 8 | 0.160 |
Why?
| | Hallucinogens | 1 | 2023 | 112 | 0.160 |
Why?
| | Brain Damage, Chronic | 2 | 1999 | 17 | 0.160 |
Why?
| | Shab Potassium Channels | 1 | 2020 | 20 | 0.160 |
Why?
| | Cannabinoids | 1 | 2023 | 182 | 0.160 |
Why?
| | Cannabidiol | 1 | 2023 | 142 | 0.160 |
Why?
| | KCNQ2 Potassium Channel | 1 | 2020 | 15 | 0.160 |
Why?
| | Epileptic Syndromes | 1 | 2020 | 98 | 0.150 |
Why?
| | Status Epilepticus | 1 | 2020 | 71 | 0.150 |
Why?
| | Self-Injurious Behavior | 1 | 2021 | 129 | 0.150 |
Why?
| | Mothers | 2 | 2023 | 772 | 0.150 |
Why?
| | Adaptation, Psychological | 2 | 2024 | 721 | 0.140 |
Why?
| | Cohort Studies | 7 | 2026 | 6077 | 0.140 |
Why?
| | Incidence | 4 | 2019 | 2936 | 0.140 |
Why?
| | Severity of Illness Index | 2 | 2026 | 2921 | 0.140 |
Why?
| | Autistic Disorder | 1 | 2021 | 216 | 0.140 |
Why?
| | Communication | 2 | 2022 | 980 | 0.130 |
Why?
| | Frontal Lobe | 1 | 1999 | 159 | 0.130 |
Why?
| | Maternal Exposure | 1 | 2019 | 189 | 0.130 |
Why?
| | Brain Waves | 1 | 2017 | 45 | 0.130 |
Why?
| | Tobacco Smoke Pollution | 1 | 2019 | 227 | 0.130 |
Why?
| | Sleep | 3 | 2020 | 896 | 0.120 |
Why?
| | Benzodiazepines | 1 | 2017 | 158 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2023 | 751 | 0.120 |
Why?
| | Obesity | 4 | 2025 | 3131 | 0.120 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2023 | 3930 | 0.120 |
Why?
| | Cannabis | 1 | 2023 | 521 | 0.110 |
Why?
| | Pregnancy | 6 | 2026 | 7230 | 0.110 |
Why?
| | Body Mass Index | 1 | 2024 | 2458 | 0.110 |
Why?
| | Overweight | 1 | 2020 | 614 | 0.110 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2012 | 92 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 3 | 2025 | 3926 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 1101 | 0.110 |
Why?
| | Stress, Psychological | 1 | 2023 | 1171 | 0.110 |
Why?
| | Perception | 1 | 2017 | 373 | 0.100 |
Why?
| | Infant, Newborn | 3 | 2022 | 6460 | 0.100 |
Why?
| | Biomarkers | 2 | 2019 | 4340 | 0.100 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 50 | 0.090 |
Why?
| | Surveys and Questionnaires | 3 | 2022 | 6073 | 0.090 |
Why?
| | Smoking | 1 | 2019 | 1486 | 0.090 |
Why?
| | Germinoma | 1 | 2012 | 10 | 0.090 |
Why?
| | Parents | 2 | 2021 | 1394 | 0.090 |
Why?
| | Whole-Body Irradiation | 1 | 2012 | 73 | 0.090 |
Why?
| | Cerebral Ventricles | 1 | 2012 | 56 | 0.090 |
Why?
| | Retrospective Studies | 8 | 2024 | 17438 | 0.090 |
Why?
| | Pediatric Nursing | 1 | 2012 | 43 | 0.090 |
Why?
| | Radiotherapy, Conformal | 1 | 2012 | 75 | 0.090 |
Why?
| | Oncology Nursing | 1 | 2012 | 35 | 0.090 |
Why?
| | Colorado | 5 | 2026 | 4595 | 0.090 |
Why?
| | Intelligence | 1 | 2012 | 119 | 0.090 |
Why?
| | Temporal Lobe | 1 | 2012 | 112 | 0.090 |
Why?
| | Aptitude Tests | 1 | 2011 | 4 | 0.080 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2012 | 143 | 0.080 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 190 | 0.080 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 303 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 89 | 0.070 |
Why?
| | Blood Glucose | 1 | 2019 | 2360 | 0.070 |
Why?
| | Insulin | 1 | 2019 | 2525 | 0.070 |
Why?
| | Middle Aged | 3 | 2026 | 36619 | 0.060 |
Why?
| | Prospective Studies | 4 | 2024 | 8123 | 0.060 |
Why?
| | Comorbidity | 2 | 2025 | 1665 | 0.060 |
Why?
| | Short Bowel Syndrome | 1 | 2006 | 24 | 0.060 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2012 | 704 | 0.060 |
Why?
| | Nutritional Support | 1 | 2006 | 39 | 0.060 |
Why?
| | Brain Ischemia | 1 | 2009 | 362 | 0.060 |
Why?
| | Neoplasms | 2 | 2012 | 2954 | 0.050 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2023 | 522 | 0.050 |
Why?
| | Gray Matter | 1 | 2025 | 96 | 0.050 |
Why?
| | Parent-Child Relations | 1 | 2026 | 266 | 0.050 |
Why?
| | Hemophilia B | 1 | 2024 | 65 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1287 | 0.050 |
Why?
| | Intelligence Tests | 1 | 2023 | 55 | 0.050 |
Why?
| | Risk Assessment | 1 | 2012 | 3712 | 0.040 |
Why?
| | Diabetic Neuropathies | 1 | 2023 | 101 | 0.040 |
Why?
| | Family Characteristics | 1 | 2023 | 203 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 417 | 0.040 |
Why?
| | Diabetes Complications | 1 | 2023 | 219 | 0.040 |
Why?
| | Treatment Outcome | 5 | 2023 | 11821 | 0.040 |
Why?
| | Maternal Inheritance | 1 | 2020 | 16 | 0.040 |
Why?
| | Language Development | 1 | 2020 | 60 | 0.040 |
Why?
| | Checklist | 1 | 2021 | 105 | 0.040 |
Why?
| | Motor Skills | 1 | 2020 | 103 | 0.040 |
Why?
| | Wechsler Scales | 1 | 1999 | 60 | 0.040 |
Why?
| | Executive Function | 1 | 2024 | 463 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2107 | 0.030 |
Why?
| | Patient Care Team | 1 | 2024 | 701 | 0.030 |
Why?
| | Inflammation | 1 | 2009 | 2919 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2024 | 881 | 0.030 |
Why?
| | Psychological Tests | 3 | 1983 | 127 | 0.030 |
Why?
| | NAV1.1 Voltage-Gated Sodium Channel | 1 | 2017 | 25 | 0.030 |
Why?
| | Fasting | 1 | 2019 | 280 | 0.030 |
Why?
| | Behavioral Symptoms | 1 | 1997 | 43 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 2019 | 329 | 0.030 |
Why?
| | Regression Analysis | 1 | 2019 | 999 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1591 | 0.030 |
Why?
| | Brain Mapping | 1 | 1999 | 541 | 0.030 |
Why?
| | Craniopharyngioma | 1 | 1997 | 77 | 0.030 |
Why?
| | Child Behavior Disorders | 1 | 1997 | 117 | 0.030 |
Why?
| | Language | 1 | 2019 | 315 | 0.030 |
Why?
| | Risk Factors | 3 | 2019 | 10921 | 0.030 |
Why?
| | Health Surveys | 1 | 2017 | 511 | 0.030 |
Why?
| | Pituitary Neoplasms | 1 | 1997 | 190 | 0.030 |
Why?
| | Homeostasis | 1 | 2019 | 646 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5439 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 1999 | 1998 | 0.030 |
Why?
| | Time Factors | 3 | 2012 | 7109 | 0.030 |
Why?
| | Health Status | 1 | 1999 | 827 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3416 | 0.020 |
Why?
| | Prognosis | 2 | 2012 | 4351 | 0.020 |
Why?
| | Organs at Risk | 1 | 2012 | 37 | 0.020 |
Why?
| | Organ Sparing Treatments | 1 | 2012 | 37 | 0.020 |
Why?
| | Neurocognitive Disorders | 2 | 1982 | 34 | 0.020 |
Why?
| | Radiotherapy Dosage | 1 | 2012 | 289 | 0.020 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 150 | 0.020 |
Why?
| | Age Factors | 2 | 2012 | 3347 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 326 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1247 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 861 | 0.020 |
Why?
| | Recurrence | 1 | 2012 | 1133 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 107 | 0.020 |
Why?
| | United States | 1 | 2026 | 16136 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 429 | 0.020 |
Why?
| | Cisapride | 1 | 2006 | 4 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 4093 | 0.010 |
Why?
| | Gastrointestinal Agents | 1 | 2006 | 63 | 0.010 |
Why?
| | Counseling | 1 | 1989 | 406 | 0.010 |
Why?
| | Dysarthria | 1 | 1984 | 10 | 0.010 |
Why?
| | Speech Disorders | 1 | 1984 | 29 | 0.010 |
Why?
| | Infant, Newborn, Diseases | 1 | 2006 | 113 | 0.010 |
Why?
| | Aluminum | 1 | 1984 | 43 | 0.010 |
Why?
| | Postoperative Complications | 1 | 1997 | 3034 | 0.010 |
Why?
| | Personality Disorders | 1 | 1984 | 79 | 0.010 |
Why?
| | Neurologic Examination | 1 | 1983 | 129 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 2 | 1984 | 2786 | 0.010 |
Why?
| | Reference Values | 1 | 1983 | 796 | 0.010 |
Why?
| | Antipsychotic Agents | 1 | 1983 | 185 | 0.010 |
Why?
| | Intellectual Disability | 1 | 1981 | 183 | 0.010 |
Why?
| | Schizophrenia | 1 | 1983 | 537 | 0.010 |
Why?
| | Health Status Indicators | 1 | 1999 | 167 | 0.010 |
Why?
| | Achievement | 1 | 1997 | 58 | 0.010 |
Why?
| | Social Behavior | 1 | 1997 | 279 | 0.010 |
Why?
| | Tremor | 1 | 1984 | 98 | 0.000 |
Why?
| | Syndrome | 1 | 1984 | 380 | 0.000 |
Why?
| | Phenothiazines | 1 | 1983 | 8 | 0.000 |
Why?
| | Aphasia, Wernicke | 1 | 1982 | 2 | 0.000 |
Why?
| | Schizophrenic Psychology | 1 | 1983 | 121 | 0.000 |
Why?
| | Kidney Failure, Chronic | 1 | 1984 | 589 | 0.000 |
Why?
|
|
Wilkening's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|